J.W. Cole Advisors Inc. Has $3.38 Million Stake in Gilead Sciences, Inc. $GILD

J.W. Cole Advisors Inc. grew its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 32.0% during the third quarter, HoldingsChannel reports. The firm owned 30,478 shares of the biopharmaceutical company’s stock after buying an additional 7,397 shares during the period. J.W. Cole Advisors Inc.’s holdings in Gilead Sciences were worth $3,383,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Brighton Jones LLC boosted its position in Gilead Sciences by 20.6% during the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after acquiring an additional 2,450 shares during the last quarter. Bison Wealth LLC acquired a new position in shares of Gilead Sciences in the 4th quarter valued at about $215,000. Sivia Capital Partners LLC boosted its position in shares of Gilead Sciences by 16.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock valued at $464,000 after purchasing an additional 602 shares in the last quarter. BankPlus Trust Department grew its stake in Gilead Sciences by 333.3% during the second quarter. BankPlus Trust Department now owns 650 shares of the biopharmaceutical company’s stock worth $72,000 after purchasing an additional 500 shares during the period. Finally, Venturi Wealth Management LLC increased its holdings in Gilead Sciences by 16.8% in the second quarter. Venturi Wealth Management LLC now owns 3,331 shares of the biopharmaceutical company’s stock worth $369,000 after purchasing an additional 479 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $149.37 on Friday. The stock has a market cap of $185.32 billion, a price-to-earnings ratio of 23.16, a PEG ratio of 0.77 and a beta of 0.36. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. Gilead Sciences, Inc. has a fifty-two week low of $93.37 and a fifty-two week high of $150.50. The firm’s 50-day simple moving average is $126.84 and its 200 day simple moving average is $120.60.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on GILD shares. HSBC boosted their price target on Gilead Sciences from $110.00 to $133.00 and gave the company a “hold” rating in a research note on Wednesday, December 10th. UBS Group increased their target price on shares of Gilead Sciences from $145.00 to $155.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Daiwa Capital Markets lifted their price target on shares of Gilead Sciences from $128.00 to $129.00 and gave the company an “outperform” rating in a research note on Thursday, November 13th. Mizuho upped their price objective on shares of Gilead Sciences from $131.00 to $140.00 and gave the company an “outperform” rating in a report on Friday, November 21st. Finally, Wells Fargo & Company raised their target price on Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a research note on Wednesday, December 10th. One analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $136.73.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, EVP Deborah H. Telman sold 53,646 shares of Gilead Sciences stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $122.85, for a total transaction of $6,590,411.10. Following the transaction, the executive vice president directly owned 43,676 shares of the company’s stock, valued at $5,365,596.60. The trade was a 55.12% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jeffrey Bluestone sold 5,000 shares of the company’s stock in a transaction on Friday, November 28th. The stock was sold at an average price of $125.08, for a total transaction of $625,400.00. Following the completion of the sale, the director owned 8,920 shares of the company’s stock, valued at approximately $1,115,713.60. The trade was a 35.92% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 257,397 shares of company stock valued at $33,385,512 over the last 90 days. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.